PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
-6.92%
Negative operating income growth while AGEN is at 16.33%. Joel Greenblatt would press for urgent turnaround measures.
121.05%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
121.15%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
115.11%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.25%
Share reduction more than 1.5x AGEN's 23.84%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
42.15%
Diluted share count expanding well above AGEN's 23.84%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-3.22%
Negative OCF growth while AGEN is at 6.21%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-8.23%
Negative FCF growth while AGEN is at 1.97%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-39049.73%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-717224.10%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-12351.82%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
45138.86%
Positive 10Y CAGR while AGEN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
41496.01%
Positive 5Y CAGR while AGEN is negative. John Neff might view this as a strong mid-term relative advantage.
7331.25%
Positive short-term CAGR while AGEN is negative. John Neff would see a clear advantage in near-term profit trajectory.
8529.17%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
2357.47%
5Y equity/share CAGR above 1.5x AGEN's 885.01%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
2495.43%
3Y equity/share CAGR 1.25-1.5x AGEN's 2139.88%. Bruce Berkowitz confirms timely buybacks or margin improvements drive stronger near-term equity growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
135.47%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
131.44%
Positive BV/share change while AGEN is negative. John Neff sees a clear edge over a competitor losing equity.
-41.82%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-18.65%
Our R&D shrinks while AGEN invests at 16.77%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
44.07%
SG&A growth well above AGEN's 13.25%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.